Fed governors may dissent against Powell amid Trump pressure - WSJ’s Timiraos
In a turbulent market environment, Alcobra Ltd (ARCT) stock has reached a 52-week low, dipping to $11.59, with a concerning beta of 2.96 indicating high volatility compared to the broader market. According to InvestingPro data, the company’s market capitalization stands at $317 million. This latest price level reflects a significant downturn for the biopharmaceutical company, which has seen its shares plummet over the past year. Investors have witnessed a stark 1-year change in the stock’s performance, with ARCT’s value eroding by -65.5%. The decline to this year’s low underscores the challenges faced by the company in a competitive sector that has been fraught with both economic uncertainties and shifting investor sentiment. InvestingPro analysis reveals concerning fundamentals, with the company burning through cash rapidly and five analysts revising earnings downward. Despite these challenges, InvestingPro’s Fair Value analysis suggests the stock may be undervalued at current levels. Get the full picture with InvestingPro’s comprehensive research report, available along with 13 additional key insights for ARCT.
In other recent news, Arcturus Therapeutics (NASDAQ:ARCT) has been the focus of several analyst updates and company developments. The company announced its full-year 2024 earnings, reporting a gross profit share of $28 million for its Kostaive product in Japan. This figure is part of a distribution partnership with Meiji and a profit split agreement with CSL (OTC:CSLLY). Meanwhile, Arcturus is making progress in its rare disease pipeline, with Phase 2 data for cystic fibrosis and ornithine transcarbamylase deficiency programs expected by the end of the second quarter of 2025.
Analyst firms have adjusted their price targets for Arcturus, reflecting these updates. BTIG raised its target to $58 while maintaining a Buy rating, citing optimism about the company’s mRNA vaccine research. Conversely, H.C. Wainwright and Canaccord Genuity reduced their targets to $60 and $68, respectively, but both maintained Buy ratings, underscoring confidence in the company’s pipeline. Leerink Partners also reduced its target to $65 but kept an Outperform rating, reflecting a positive outlook despite the adjustment.
Arcturus’s ongoing research in mRNA vaccines, including potential treatments for influenza and cystic fibrosis, remains a key focus. Analysts have highlighted the potential market value of these programs, particularly given the significant sales achieved by existing cystic fibrosis treatments like TRIKAFTA. The company’s innovative approach in its research and development efforts continues to be a point of interest for investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.